echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Targeting Claudin 18.2 and 4-1BB!

    Targeting Claudin 18.2 and 4-1BB!

    • Last Update: 2021-04-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Source: Guanlan Pharmaceutical

    On March 30th, Tianjing Bio and South Korea’s ABL Bio jointly announced that the bispecific antibody TJ-CD4B (also known as ABL111) that targets Claudin 18.


    TJ-CD4B is an innovative bispecific antibody that simultaneously targets the tumor antigen claudin 18 splice 2 (Claudin 18.


    Preclinical studies have shown that even in the case of low expression of Claudin 18.


    This time, approved in the United States is a multi-center Phase 1 dose-climbing trial, which will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of TJ-CD4B in patients with advanced or metastatic solid tumors.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.